FGFR1 and neoplasm: Patients with low FGFR1-expressing HNPC had a mean time to relapse of 3.9 years, whereas patients with tumours showing high cytoplasmic FGFR immunoreactivity relapsed quicker with a mean time to relapse of 2.1 years (P=0.006; Figure 4C).